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Effect of antibiotics on sputum inflammatory contents in 
acute exacerbations of bronchiectasis 
M. IP*, D. SHuMt, I. LAUDERS, W. K. LAM* AND S. Y. So* 
Departments of *Medicine, -fBiochemistry, and $Statistics, University of Hong Kong, Hong Kong 
We studied the changes in sputum neutrophil chemotactic activity (NCA) and elastolytic activity (EA) in acute 
exacerbations of bronchiectasis before and after treatment with oral antibiotics. Twelve patients who chronically 
produced sputum were assessed in the stable state, and when they subsequently developed symptoms of acute 
exacerbations, prior to initiation of antibiotics, during 2 weeks of antibiotics, and at 2 and 6 weeks after stopping 
antibiotics. NCA was measured using modified Boyden’s technique with multiwell chemotaxis chamber, and EA 
with N-succiny-trialanine-p-nitroanilide as elastase substrate. All 12 patients had NCA (49.3 f 8.69% FMLP 
response) and EA (50.5 f 17.1 mU per 100 ~1) in their sputum in the stable state. At acute exacerbation, there was 
significant increase in NCA (P < 0.001) and EA (P < 0.05). All responded clinically after 1 week of antibiotics, 
and this was associated with a decrease in NCA and EA back to the levels in stable state. A further week of 
antibiotics did not result in further decline of NCA or EA. Three patients had another acute exacerbation 
clinically between 2-6 weeks after stopping antibiotics and their NCA and EA rose again. In the other nine 
patients, both NCA and EA at 2 and 6 weeks post-treatment were similar to pre-exacerbation levels. Our findings 
suggest that short course antibiotics effectively control the upsurge in inflammatory activity in acute axacerba- 
tions, but has little effect on chronic airway inflammation. This would challenge the validity of such a treatment 
strategy which is still the most common in clinical practice, when persistent airway inflammation is believed to 
lead to progressive lung destruction. 
Introduction 
Antibiotic therapy is the mainstay treatment of 
infective exacerbations in bronchiectasis. Clinically, 
response to treatment is manifested by a decrease in the 
volume and purulence of sputum. Microbiologically, 
there is a reduction in the bacterial load in the 
bronchial tree (1). Associated with this change in 
macroscopic appearance of sputum and reduction of 
bacterial load, one can anticipate a decrease in many 
of the inflammatory contents as well. There have 
been no studies on the changes in inflammatory 
contents in the airways in acute exacerbations of 
bronchiectasis such as elastase activity and neutrophil 
chemotactic activity, and their response to antibiotic 
treatment. 
The purpose of our study was to investigate the 
course of changes in airway inflammatory activity 
and lung function before, during and after an acute 
exacerbation of chronic bronchial infection in bron- 
chiectasis, treated with a course of antibiotics as in 
usual clinical practice. 
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Materials and Methods 
Twelve patients were recruited from the Bronchiectasis 
Clinic, Queen Mary Hospital. 
A cross-sectional study of sputum inflammatory 
contents and lung function test in the stable clinical 
state in bronchiectasis has been previously conducted 
in a cohort of patients in this clinic. They have 
been followed up regularly and were approached for 
recruitment into the present study when they devel- 
oped acute infective exacerbation. All 12 patients gave 
informed consent. 
Criteria for entry into the study were: 
1. Bronchiectasis diagnosed by clinical symptoms 
and radiologic confirmation on CXR or bronchogram 
or computerized tomography of thorax. 
2. In acute exacerbation as evidenced by increase in 
purulence and volume of sputum with or without fever 
or chest pain. 
3. No other clinical exacerbation in the past 4 weeks. 
4. No antibiotics taken in the past 4 weeks. 
5. Had sputum assessment and lung function test 
done at least once in the stable state in the past 6 
months. 
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Prior to any treatment, clinical assessment, lung 
function tests, and sputum collection were done. Anti- 
biotics were then prescribed for 2 weeks. Subsequent 
evaluations were done at 1, 2,4 and 8 weeks after the 
initiation of antibiotic therapy. 
The antibiotic regime of Ofloxacin 300mg twice 
daily for 14 days was used. This has been shown in 
a previous study conducted in our department to be 
effective in the treatment of acute exacerbations in 
bronchiectasis (2) and was therefore a routine regime 
used in our clinic. If the patient did not improve clini- 
cally after 1 week of treatment, antibiotic treatment 
was changed, guided by microbiology results. 
Sputum assessment included: bacterial culture, 
volume, purulence, polymorph count, neutrophil 
chemotactic activity and elastolytic activity. 
SPUTUM VOLUME 
Sputum was collected into scaled containers for 24 h 
prior to clinic visit for estimation of volume, and scored 
as follows: O-20 ml day-’ = I, > 20-50 ml day-’ = 2, 
> 50 ml day-’ = 3. Sputum expectorated in the 4 h 
from rising in the morning of clinic visit was collected 
in a separate sterile scaled container to facilitate other 
tests which need fresh sputum specimens, including 
polymorph (PMN) count, neutrophil chemotactic 
activity (NCA), elastolytic activity (EA) and bacterial 
culture. 
SPUTUM COLOUR 
This was noted by the same assessor and classified as 
follows: mucoid, 1; mucopurulent, 2; purulent, 3. 
SPUTUM POLYMORPH COUNT 
Sputum smears were treated with Wright’s stain. 
Specimens with predominance of epithelial cells had 
been excluded. An average PMN in five fields at x 400 
magnification (high power field, hpf) was t‘aken and 
scored as follows: < 20 PMNjhpf, 1; 2(r50 PMN/hpf, 
2; > 50 PMN/hpf, 3. 
SPUTUM NEUTROPHIL CHEMOTACTIC ACTIVITY 
Sputum was collected in sterile containers over 4 h in 
the morning. Samples were then ultracentrifuged 
(50 OOOg for 90 min at 4°C) and the supernatant 
(sol phase) was harvested. This was stored in 100~1 
aliquots at - 70°C until assayed. 
For NCA assay, sputum sol were diluted 1:5 (by 
volume) with HEPES solution containing 2 mg ml-’ 
of bovine serum albumin (BSA). Polymorphs were 
isolated from peripheral blood of normal subjects 
using Percoll gradient method (3). Neutrophil chemo- 
tactic activity was measured with a modification of 
the Boyden technique, using multiwell chemotaxis 
chamber (4). The chamber (Neuroprobe Incorp., 
U.S.A.) consisted of two silicon slabs with 48 open 
wells in the top compartment and 48 corresponding 
blind wells in the lower compartment. Twenty-six 
microlitres of chemo-attractant, sputum sol, was placed 
in the lower chamber, and 50 ~1 PMN suspension, at 
a concentration of 1.5 x lo6 ml-’ was placed in the 
upper. The upper and lower chambers were separated 
by a polyvinylpyrrolidone-free polycarbonate mem- 
brance of mean pore diameter of 2,um (Nucleopore 
Corp., U.S.A.) to ensure PMN adhesion. Control 
samples contained medium without chemo-attractant 
in the lower well (negative control) or a standard 
chemo-attractant FMLP IO-*M in the lower well 
(positive control). Each sample was assayed in tripli- 
cate. The polymorphs would migrate in accordance 
with the attraction gradient across the membrane and 
adhere to the undersurface. 
After incubation at 37°C for 30 min, the membrane 
was removed, washed with phosphate-buffered saline 
and the excess cells were scraped off with a rubber 
wiper. The membrane was then air-dried, fixed and 
stained with Diff-quik (Baxter Incorp., U.K.). It was 
then examined under the microscope at x 400 magnifi- 
cation and the number of PMN present in five random 
fields were counted and the mean obtained for each 
well. The average value of the three wells containing 
the same sample was taken as the result for that 
sample. Since the polymorphs used were harvested 
from different individuals, and sputum samples were 
assayed in many batches, results were expressed as 
percentage of response to FMLP in the same chamber 
to eliminate any inter-assay variation and variation 
due to the polymorphs. 
SPUTUM ELASTASE-LIKE ACTIVITY 
Sputum sol was prepared as described above. 
Elastase-like content was measured as amidolytic 
activity using N-succinyl-trialanine-p-nitroanilide 
(SLAPN), a synthetic polypeptide (5). SLAPN is 
cleaved by elastase-like substances, producing a 
change in light absorbance that is measured spectro- 
photometrically. The assay mixture consisted of 200 ~1 
of sputum sol, 20 ~1 of SLAPN (Peptide Institute Inc., 
Japan) dissolved in N-methylpyrrolidone and 1780 ~1 
of assay buffer (0.2 M Tris-HCl, pH 8.0). The mixture 
was incubated at 37°C for 30 min. After the period of 
incubation, 100 ~1 of acetic acid was added to stop the 
enzyme reaction and activity was measured at 410 nm 
wavelength with the spectrophotometer (CE272 Linear 
Readout UV Spectrophotometer, Cecil Instruments, 
U.K.). Each sputum sample was assayed in triplicate 
and the mean value was used as the final result. Known 
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concentrations of porcine pancreatic elastase (Sigma 
Chemical Co., U.S.A.) were used to construct a 
standard curve, which was then used to determine the 
elastase-like activity in the sputum sol samples. 
LUNG FUNCTION TESTS 
Lung function tests were performed with Gould 
50001V Computerized Lung Function System. Spiro- 
metric data including forced vital capacity (FVC), 
forced expiratory volume in one second (FEV,), forced 
expiratory flow at 50% vital capacity (FEF,,) were 
measured. 
STATISTICAL ANALYSIS 
Data at exacerbation and subsequent assessments 
were compared with the baseline in each individual. 
Change from baseline was then analysed for statistical 
significance using one sample Wilcoxon’s test. This 
method of analysis would eliminate the problem of 
changes introduced by the withdrawal of three patients 
after the first 2 weeks of study. 
Results 
Twelve patients were recruited into the study. The 
diagnosis of bronchiectasis was based on broncho- 
gram in two, computerized tomography of thorax in 
five, and plain chest films in five (all of whom showed 
gross cystic bronchiectatic changes). All had been 
chronically producing mucopurulent or purulent 
sputum, and developed an acute exacerbation of 
symptoms at IO-20 weeks after collection of baseline 
data. Sputum culture grew Pseudomonas aeruginosa in 
six (five were chronically colonized), Haemophilus 
injluenzae in two, Streptococcus pneumoniae in one, 
and only commensals in three. All responded sympto- 
matically to the 2 weeks course of antibiotics, but three 
relapsed clinically within the 6 weeks follow-up period. 
Their data were analysed up to the visit prior to relapse. 
Table 1 shows the changes of the various parameters 
during the study period, with reference to their values 
in the stable state. Figures 1-4 show the group data of 
sputum NCA and EA, FEV, and FEF,, throughout 
the study period. 
There was significant upsurge in sputum NCA and 
EA at acute exacerbation prior to treatment. With 
antibiotics, their levels were significantly decreased, 
but they only returned to baseline. There was no sig- 
nificant difference at 1 week and 2 weeks of treatment. 
They remained stable up to 6 weeks after cessation of 
antibiotic treatment except in the three patients who 
relapsed clinically, in whom the levels increased again. 
Apart from a decrease in FEF,, at acute exacerbation 
(P < O-05), which returned to baseline after antibiotics, 
there was no significant change in other lung function 
parameters. 
Discussion 
The clinical spectrum of bronchiectasis ranges from 
episodic infections with minimal symptoms in between 
to chronic copious purulent sputum production. 
Treatment has been problematic in those who have 
persistent symptoms. Long-term antibiotics have been 
largely avoided for fear of inducing drug resistant 
organisms. The disease runs a chronic course and 
patients are considered to be ‘stable’ most of the time. 
Hence, patients are only given short courses of anti- 
biotics intermittently for clinical exacerbations, and 
treatment is aimed at an improvement of sympto- 
matology back to their basal level, rather than total 
abolition of symptoms in most cases. 
Persistent airway inflammation is postulated to be a 
key pathogenetic factor in chronic bronchial sepsis 
(6,7), and neutrophil-mediated mechanisms probably 
play an important role in the vicious circle of inflam- 
mation (8). Neutrophils are recruited in abundance to 
the airways in bronchiectasis as shown on sputum 
cytology (9) and radionuclide studies (10). Sputum 
from patients with bronchiectasis in the stable clinical 
state has been shown to contain neutrophil chemo- 
tactic activity (NCA) (1 l), which is believed to attract 
neutrophils to the airways. Hence it is logical to 
assume that the more NCA there is, the more active the 
neutrophil influx, and the subsequent inflammation. 
Elastolytic activity (EA), mostly of neutrophil source, 
has been demonstrated to be present in varying degrees 
in sputum from cystic fibrosis (12), bronchiectasis (9) 
and infective exacerbations of chronic bronchitis (13). 
Elastase has the capability to injure tissue (14) and is 
believed to contribute to lung destruction and deterio- 
ration in lung function in chronic bronchial infections 
(9,14). Both NCA and EA in sputum from patients 
with bronchiectasis in the stable clinical state have 
been shown to be suppressed temporarily by antibiotic 
treatment (11,15). 
Our study follows the course of changes in sputum 
inflammatory contents and lung function before, 
during and after an acute infective episode treated 
with antibiotics in a group of patients who chronically 
produce mucopurulent or purulent sputum. Their 
sputum contained NCA and EA in the stable clinical 
state. Our results show that with clinical exacerbation, 
there was a significant upsurge in NCA and EA, and 
confirm that antibiotics effectively reduced airway 
inflammation as demonstrated by a marked decrease 
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Fig. 1 Sputum neutrophil chemotactic activity (mean f SEM) 
of nine patients who completed the study (0-O) and 
three patients who relapsed (A----A). B, baseline; E, 
exacerbation. 
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Fig. 2 Sputum elastase-like activity (mean+%@ of nine 
patients who completed the study (e-0) and three 
patients who relapsed (A----A). B, baseline; E, 
exacerbation. 
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Fig. 3 FEV, (mean f SEM) of nine patients who completed 
the study (0-O) and three patients who relapsed 
(A----A). B, baseline; E, exacerbation. 
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Fig. 4 FEF, (mean f SEM) of nine patients who completed 
the study (0-O) and three patients who relapsed 
(A----A). B, baseline; E, exacerbation. 
in NCA and EA after 1 week treatment. However, they 
only returned to the basal level and did not decrease 
any further after another week of antibiotics. 
Changes in lung function in relation to exacerbations 
and antibiotic therapy have been variable in different 
studies. Significant improvement has been reported by 
some investigators (1) while no change was found by 
another group (16). We have not found any significant 
difference in lung function tests apart from a decrease 
in FEF, at exacerbation, which responded to treat- 
ment with antibiotics. The lack of change with one 
acute episode supports the clinical observation that 
lung function deterioration in bronchiectasis is an 
insidious process. 
These findings suggest that short course antibiotics 
as used in acute exacerbations effectively control the 
increase in inflammatory activity but are inadequate in 
dealing with the persistent airway inflammation. In 
particular, these patients have a basal level of airway 
inflammatory activity. This may be related to a failure 
to eradicate the colonizing microorganisms, which 
therefore continue to incite host defence response. 
On the other hand, the fact that the respiratory tract 
may be colonized by bacteria without evoking this 
prominent continuous inflammatory reaction suggests 
that other factors are involved. It is likely that host 
defence mechanisms have been tuned up with the 
tendency to amplify and perpetuate the inflammatory 
response. Since airway inflammation is a key factor in 
the pathogenetic mechanisms in chronic bronchial 
infection, and may contribute to lung destruction, 
treatment strategies should ultimately aim at decreas- 
ing the inflammatory load in the bronchial tree. 
Studies with higher dose or long-term antibiotics have 
shown better clinical response and reduction of lung 
inflammation for longer duration after cessation of 
454 M. Ip et al. 
treatment in patients with chronic bronchial infection 
(1,16,17), suggesting their potential value in reducing 
lung destruction, and further studies of these modes of 
antibiotic administration are clearly indicated. With 
recent evidence that anti-inflammatory agents may 
attenuate the inflammatory response in chronic pul- 
monary infection (18-20), such adjunctive therapeutic 
measures, especially between infective exacerbations 
in chronic bronchial sepsis, should be further explored. 
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